The biotech sector's endured an up-and-down 2014 after the immense gains captured in 2013's market rise, but don't tell that to fast-rising Biogen Idec (NASDAQ:BIIB). Biogen's stock has roared higher by more than 10% in 2014 after experiencing a tremendous run-up last year, topping the charts among big biotech stocks and giving hope to investors across the industry. Biogen's hit a home run with multiple sclerosis drug Tecfidera, which reeled in nearly $400 million in sales in the past quarter, but this company's not sitting still waiting for its next big success story.

Biogen scored again for investors recently when the Food and Drug Administration approved the company's developmental hemophilia B treatment Alprolix. While Biogen's relatively inexperienced in the hemophilia market, it's gearing up for a big push, and Alprolix is the first stepping stone to Biogen's plans for dominance in a market that heavyweights such as Pfizer (NYSE:PFE) and Bayer (NASDAQOTH:BAYRY) are fighting for.

Can Biogen score another investor success from the hemophilia market? Find out all about Alprolix's success -- and what Biogen plans to do for an encore -- in the video below as Motley Fool contributor Dan Carroll takes you through the latest in one of big biotech's hottest stocks.

Will Biogen top the charts in 2014?
Biogen's laid out an outstanding performance for investors lately, but one maxim's true in the markets: There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Dan Carroll has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.